The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala

Published on November 22, 2019

CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and the biotech Domain Therapeutics was awarded the RSRI Recognition Award during the ADRIQ Innovation Prize Gala held on November 21st.

This CQDM-funded project has received $1.8M over three years for the development of a GPCR‑Specific Biosensor Technology. GPCRs are membrane proteins that offer tremendous potential in pharmacological research to monitor the efficacy of drugs at the cellular level. Based on a public-private partnership, Michel Bouvier’s project exemplifies the collaborative approach promoted by CQDM.

This project involved several research groups from various academic institutions including the laboratories of Michel Bouvier (IRIC), Stéphane Laporte and Terry Hebert (McGill University), Graciela Pineyro (Centre de recherche de l’hôpital Sainte-Justine et Richard Leduc (Université de Sherbrooke), as well as the biotech Domain Therapeutics and the world-leading pharmaceutical organizations Pfizer and Merck. Beyond the collaboration between the academic and industrial sectors, this project also fostered international cooperation between Quebec and France.

Source: CQDM

Read the entire press release